MacroGenics, Inc.
General ticker "MGNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $110.3M (TTM average)
MacroGenics, Inc. follows the US Stock Market performance with the rate: 39.4%.
Estimated limits based on current volatility of 2.9%: low 3.96$, high 4.20$
Factors to consider:
- Total employees count: 339 (-5.0%) as of 2023
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Clinical development risks, Manufacturing risks, Public health crises, Patent risks, Cybersecurity threats
- Current price 28.1% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.15$, 3.28$]
- 2026-12-31 to 2027-12-31 estimated range: [1.41$, 3.77$]
Financial Metrics affecting the MGNX estimates:
- Positive: with PPE of -1.4 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: 19.24 < Shareholder equity ratio, % of 21.64 <= 42.59
Short-term MGNX quotes
Long-term MGNX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $58.75MM | $149.96MM | $149.50MM |
| Operating Expenses | $226.99MM | $260.54MM | $222.34MM |
| Operating Income | $-168.24MM | $-110.58MM | $-72.84MM |
| Non-Operating Income | $159.19MM | $44.56MM | $-2.45MM |
| Interest Expense | $1.43MM | $1.11MM | $8.51MM |
| R&D Expense | $166.58MM | $177.19MM | $147.17MM |
| Income(Loss) | $-9.06MM | $-66.02MM | $-75.29MM |
| Taxes | $0.00MM | $0.94MM | $-0.67MM |
| Net Income(Loss)* | $-9.06MM | $-66.97MM | $-74.62MM |
| Stockholders Equity | $152.61MM | $116.06MM | $55.59MM |
| Inventory | $1.22MM | $0.00MM | $7.91MM |
| Assets | $298.42MM | $261.65MM | $256.85MM |
| Operating Cash Flow | $-78.20MM | $-68.37MM | $-81.04MM |
| Capital expenditure | $1.76MM | $3.71MM | $1.91MM |
| Investing Cash Flow | $-80.08MM | $149.30MM | $-114.10MM |
| Financing Cash Flow | $150.36MM | $0.96MM | $69.51MM |
| Earnings Per Share** | $-0.15 | $-1.07 | $-1.18 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.